Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Pulmonx CorporationNASDAQ: LUNG
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -66.3%
Net margin was -66.3% in Q1 FY2026, down 2.2 pp from a year earlier. On a trailing-twelve-month basis it was -60.1%, up 5.2 pp year over year. Over 3 fiscal years it widened by 50.1 pp.
Context
- Net margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of -42.8% for the fiscal year ending Dec 2026, up from -59.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -66.3%-20.2 pp QoQ
- Last fiscal yearDec 2025
- -59.7%+7.6 pp YoY
- LTMMar 2026
- -60.1%+5.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.2 pp | +9.6 pp | +11.8 pp |
| 1 year | +7.6 pp | +16.9 pp | +9.2 pp |
| 3 years | +50.1 pp | +32.5 pp | -17.6 pp |
| 5 years | +48.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -59.7%
- Year-over-year change
- +7.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -59.7% | +7.6pp |
| FY2024 | 2024-12-31 | -67.3% | +21.3pp |
| FY2023 | 2023-12-31 | -88.6% | +21.2pp |
| FY2022 | 2022-12-31 | -109.8% | -9.3pp |
| FY2021 | 2021-12-31 | -100.5% | — |
Net Margin vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 net margin of -60.1% is the 4th highest of the 6 companies compared; the peer median is -51.5%.
- Its year-over-year change of +5.2 pp is the 4th highest of 6, against a peer median of +116.5 pp.
- Over three fiscal years its change of +50.1 pp compares with a peer median of +58.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 14.5% | +137.1 pp | +100715.3 pp | |
| LTM Mar 2026 | -34.9% | -9.2 pp | -95.8 pp | |
| LTM Jun 2026 | -51.5% | +2.6 pp | +58.6 pp | |
| LTM Mar 2026 | -60.1% | +5.2 pp | +50.1 pp | |
| LTM Mar 2026 | -226.9% | +116.5 pp | +811.4 pp | |
| LTM Mar 2026 | -1360.6% | +1613.5 pp | -767.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding LUNG) | -51.5% | +116.5 pp | +58.6 pp | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.42M | 53.66M | 68.68M | 83.79M | 90.5M |
| Cost of Revenue | 12.79M | 13.8M | 17.92M | 21.79M | 23.36M |
| Gross Profit | 35.63M | 39.87M | 50.75M | 62M | 67.14M |
| Gross Margin | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Research & Development | 13.06M | 15.4M | 18.08M | 17.57M | 19.49M |
| Selling, General & Admin | 69.87M | 83.11M | 94.61M | 102.14M | 101.31M |
| Operating Expenses | 82.93M | 98.5M | 112.69M | 119.71M | 120.8M |
| Depreciation & Amortization | 867K | 1.51M | 1.95M | 1.59M | 1.05M |
| EBITDA | (46.62M) | (55.99M) | (55.09M) | (50.79M) | (49.17M) |
| EBITDA Margin | -96.3% | -104.3% | -80.2% | -60.6% | -54.3% |
| Operating Income | (47.3M) | (58.64M) | (61.94M) | (57.7M) | (53.66M) |
| Operating Margin | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
| Interest Income | 400K | 1.53M | 5.57M | 5.06M | 2.65M |
| Interest Expense | 829K | 1.07M | 3.23M | 3.51M | 3.16M |
| Other Income / Expenses | (1.01M) | 67K | 1.66M | 1.81M | 286K |
| Income Before Tax | (48.32M) | (58.57M) | (60.27M) | (55.89M) | (53.38M) |
| Pre-Tax Margin | -99.8% | -109.1% | -87.8% | -66.7% | -59.0% |
| Income Tax Expense | 343K | 353K | 571K | 500K | 626K |
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Net Margin | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| EPS (Basic) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| EPS (Diluted) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| Weighted Avg Shares | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
| Weighted Avg Shares (Diluted) | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.